121 related articles for article (PubMed ID: 21454220)
1. Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.
Sun JY; Xu L; Tseng H; Ciccarelli B; Fulciniti M; Hunter ZR; Maghsoudi K; Hatjiharissi E; Zhou Y; Yang G; Zhu B; Liu X; Gong P; Ioakimidis L; Sheehy P; Patterson CJ; Munshi NC; O'Connor OA; Treon SP
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):152-6. PubMed ID: 21454220
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.
Sacco A; Ghobrial IM; Roccaro AM
Curr Cancer Drug Targets; 2011 Nov; 11(9):1025-9. PubMed ID: 21933107
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
Roccaro AM; Leleu X; Sacco A; Moreau AS; Hatjiharissi E; Jia X; Xu L; Ciccarelli B; Patterson CJ; Ngo HT; Russo D; Vacca A; Dammacco F; Anderson KC; Ghobrial IM; Treon SP
Clin Cancer Res; 2008 Mar; 14(6):1849-58. PubMed ID: 18347188
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
Kiliccioglu I; Konac E; Varol N; Gurocak S; Yucel Bilen C
Genet Mol Res; 2014 May; 13(2):3721-31. PubMed ID: 24854658
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
[TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
7. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
[TBL] [Abstract][Full Text] [Related]
8. [Waldenström's macroglobulinemia].
Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
[TBL] [Abstract][Full Text] [Related]
9. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
Roccaro AM; Sacco A; Chen C; Runnels J; Leleu X; Azab F; Azab AK; Jia X; Ngo HT; Melhem MR; Burwick N; Varticovski L; Novina CD; Rollins BJ; Anderson KC; Ghobrial IM
Blood; 2009 Apr; 113(18):4391-402. PubMed ID: 19074725
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
11. Role of proteasome inhibition in Waldenström's macroglobulinemia.
Roccaro AM; Sacco A; Leleu X; Azab AK; Azab F; Runnels J; Jia X; Ngo HT; Melhem M; Moreau AS; Ghobrial IM
Clin Lymphoma Myeloma; 2009 Mar; 9(1):94-6. PubMed ID: 19362985
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
[TBL] [Abstract][Full Text] [Related]
14. Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.
Sun JY; Tseng H; Xu L; Hunter Z; Ciccarelli B; Fulciniti M; Zhu B; Maghsoudi K; Yang G; Gong P; Zhou Y; Liu X; Munshi NC; Patterson CJ; Treon SP
Leuk Lymphoma; 2011 Sep; 52(9):1777-86. PubMed ID: 21657958
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
[TBL] [Abstract][Full Text] [Related]
16. Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
Asklund T; Kvarnbrink S; Holmlund C; Wibom C; Bergenheim T; Henriksson R; Hedman H
Anticancer Res; 2012 Jul; 32(7):2407-13. PubMed ID: 22753697
[TBL] [Abstract][Full Text] [Related]
17. Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Mitsiades CS; Mitsiades N; Richardson PG; Treon SP; Anderson KC
Semin Oncol; 2003 Apr; 30(2):309-12. PubMed ID: 12720159
[TBL] [Abstract][Full Text] [Related]
18. Current and future therapeutic approach for Waldenström's macroglobulinemia.
Souchet-Cömpain L; Choquet S; Leblond V; Nguyen S
Immunotherapy; 2014; 6(3):333-48. PubMed ID: 24762077
[TBL] [Abstract][Full Text] [Related]
19. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Yu C; Friday BB; Yang L; Atadja P; Wigle D; Sarkaria J; Adjei AA
Neuro Oncol; 2008 Jun; 10(3):309-19. PubMed ID: 18445700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]